JavaScript is NOT enabled !

Please enable JavaScript.

* Show help

Author: Silverman, Ian M

1 hits in Medvik Filters

Article

CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study

Duell, Johannes
Author Duell, Johannes Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany
Obr, Aleš
Author Authority ORCID Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic
Augustin, Marinela
Author Augustin, Marinela Klinik für Innere Medizin 5, Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Nürnberg, Germany
Endell, Jan
Author Endell, Jan MorphoSys AG, Planegg, Germany
Liu, Hao
Author Liu, Hao Incyte Research Institute, Wilmington, DE, USA
Geiger, Sabine
Author Geiger, Sabine MorphoSys AG, Planegg, Germany
Silverman, Ian M
Author Silverman, Ian M Incyte Research Institute, Wilmington, DE, USA
Ambarkhane, Sumeet
Author Ambarkhane, Sumeet MorphoSys AG, Planegg, Germany
Rosenwald, Andreas
Author Rosenwald, Andreas Institute of Pathology, University of Würzburg, Würzburg, Germany

Leukemia & lymphoma. 2022 ; 63 (2) : 468-472. [pub] 20211115

Leuk Lymphoma
ISSN 1029-2403
Medvik
Source

MeSH
Lymphoma, Large B-Cell, Diffuse * drug therapy etiology MeSH
Antibodies, Monoclonal, Humanized * therapeutic use MeSH
Lenalidomide MeSH
Humans MeSH
Antineoplastic Combined Chemotherapy Protocols MeSH
Check Tag
Humans MeSH
Publication type
Letter MeSH
Research Support, Non-U.S. Gov't MeSH